Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Strategic focus on exploratory investigator-initiated clinical studies with institutional partners
Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma
FRAMINGHAM, MA / ACCESS Newswire / March 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ('Xenetic' or the 'Company'), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2024.
Recent Highlights
Extended its collaborations with the University of Virginia and Scripps Research through 2025;
Entered into a Clinical Trial Services Agreement with PeriNess Ltd. to manage investigator initiated exploratory studies of DNase I in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors; and
Continued pursuit of other strategic collaborations to advance the Company's technology.
'Over the course of 2024, our team made notable advancements across multiple fronts. We continued to establish and present a growing body of preclinical data that supports the use of our DNase-based technology across several cancer indications. Additionally, we continued to engage institutional partners to drive our development strategies forward including investigator-initiated studies and partnering on various other efforts. Leveraging these relationships allows us to advance our technology toward the clinic while utilizing our resources efficiently and minimizing our internal investment. Looking ahead to 2025, we are executing on our initiatives as we progress toward an IND and Phase 1 clinical trial and look forward to an exciting year,' commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.
Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Preliminary preclinical studies evaluating the combinations of DNase I with chemotherapy and DNase I with immuno-therapies in colorectal cancer models as well as CAR-T therapy have been completed.
Summary of Financial Results for Fiscal Year 2024
Net loss for the year ended December 31, 2024 was approximately $4.0 million. Research and development expenses for the year ended December 31, 2024 decreased by approximately $0.2 million, or 5.9%, to $3.3 million from $3.5 million in the prior year period. This decrease was primarily due to decreased spending in connection with the Company's DNase process development efforts. Royalty payments received from the Company's sublicense with Takeda Pharmaceuticals Co. Ltd in the year ended December 31, 2024 were approximately $2.5 million, relatively flat with that of the year ended December 31, 2023. General and administrative expenses for the year ended December 31, 2024 were $3.4 million, decreasing by approximately $0.1 million, or 4.1%, compared to the prior year. The decrease was primarily due to a reduction in legal and accounting costs during the year ended December 31, 2024 compared to the prior year. These decreases were substantially offset by certain severance and benefits expensed in connection with a separation agreement entered into during the second quarter of 2024.
The Company ended the year with approximately $6.2 million of cash.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as 'expects,' 'plans,' 'projects,' 'will,' 'may,' 'anticipates,' 'believes,' 'should,' 'intends,' 'estimates,' 'remain,' 'focus', 'confidence in', 'potential', and other words of similar meaning, including, but not limited to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: executing on our initiatives as we progress toward an IND and Phase 1 clinical trial, our forward outlook for an exciting year, plans to advance our DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors, our focus on advancing innovative immune-oncology technologies addressing difficult to treat cancers, the DNase technology improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
JTC Team, LLC
Jenene Thomas
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
The Best Growth Stock ETF to Invest $100 in Right Now
Key Points It's hard to know which stocks will be tomorrow's winners, so it makes sense to buy a bundle of them. The Vanguard Growth ETF boasts a great track record and ultra-low fees to its investors. Do remember that in market downturns, growth stocks tend to fall harder than the overall market. 10 stocks we like better than Vanguard Index Funds - Vanguard Growth ETF › If you're like many investors, you either own or want to own the "Magnificent Seven" stocks, which are Apple, (Google parent) Alphabet, (Facebook parent) Meta Platforms, Microsoft, Nvidia, and Tesla. You might also want to own companies that could become Magnificent-Seven-like -- in other words, terrific growth stocks. But which companies are the next great investments? It can be hard to know, which is why it's smart to buy a bundle of promising stocks, spreading your risk and opportunity around. Consider, therefore, investing in the Vanguard Growth ETF (NYSEMKT: VUG), which you can do with as little as $100. (To clarify, a single share recently went for $463, so if you only had $100 to invest, you'd need to buy a fraction of a share, which some good brokerages allow you to do.) An exchange-traded fund (ETF) is a fund that trades like a stock. Meet the Vanguard Growth ETF The Vanguard Growth ETF tracks the CRSP U.S. Large Cap Growth Index, which is focused on large-cap companies growing at a faster-than-average clip, and the ETF aims to deliver roughly the same returns, minus its low fees. Specifically, its expense ratio (annual fee) is just 0.04%, meaning that you'll be charged a whopping $4 per year for every $10,000 you have invested in the fund. The ETF held 165 stocks, as of June 30, per Vanguard, with 60% of assets in the technology sector, followed by 19% in the consumer discretionary sector. Here are the top 10 holdings, which together made up about 59% of total assets: Stock Weight in ETF Microsoft 11.76% Nvidia 11.63% Apple 9.71% 6.53% Meta Platforms 4.57% Alphabet Class A 4.26% Alphabet Class C 3.17% Eli Lilly 2.87% Broadcom 2.55% Tesla 2.19% Source: as of June 30. You can see that all the Magnificent Seven stocks are there -- and among the top holdings. And given that these 10 holdings make up more than half the ETF's value, it's clear that the other 155 stocks will be relatively minor holdings for the ETF -- and its shareholders. Still, those top 10 companies are in the top 10 because they grew to huge sizes, and it's not crazy to let your winners run and keep winning. This ETF and its more well-known fellow index fund, the S&P 500 index fund, are, like lots of others, market-cap-weighted, meaning that the bigger the component company, the more influence it will wield on the index. That's why the top 10 companies above make up so much of the Vanguard Growth ETF's value -- because they have such hefty market caps. If you're in the market for diversification with less concentration, you might look for a good equal-weighted ETF, such as the Invesco S&P 500 Equal Weight ETF, which holds each of its 500-some components in roughly equal proportion. The Invesco equal-weight ETF's top-10 holdings would, therefore, make up only about 2% or 3% of the overall ETF value. How has the Vanguard Growth ETF performed? Here's how the Vanguard Growth ETF would have rewarded you over several recent periods. I'll compare its numbers to those of a low-fee S&P 500 index fund, too, and you'll see that it outperformed the S&P index fund handily: Time period Vanguard Growth ETF Vanguard S&P 500 ETF Past 3 years 21.22% 16.30% Past 5 years 16.47% 15.46% Past 10 years 16.58% 13.89% Past 15 years 17.00% N/A Source: as of August 12, 2025. There's no guarantee that it will always outperform, though, and it's good to remember that since growth stocks tend to fall harder in market downturns, there may be years when it really underperforms. For example, in 2022, when the S&P 500 ETF dropped by around 18%, the Vanguard Growth ETF dropped by 33%. Ouch! Still, long-term investors have enjoyed solid overall gains, and it's rarely good to focus on any one year. So go ahead and consider the Vanguard Growth ETF for your growth-stock needs. But perhaps complement it with some other solid index ETFs. Should you buy stock in Vanguard Index Funds - Vanguard Growth ETF right now? Before you buy stock in Vanguard Index Funds - Vanguard Growth ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vanguard Index Funds - Vanguard Growth ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Selena Maranjian has positions in Alphabet, Amazon, Apple, Broadcom, Meta Platforms, Microsoft, Nvidia, and Vanguard Index Funds-Vanguard Growth ETF. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, Tesla, and Vanguard Index Funds-Vanguard Growth ETF. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. The Best Growth Stock ETF to Invest $100 in Right Now was originally published by The Motley Fool
Yahoo
a minute ago
- Yahoo
At US$237, Is It Time To Put Lincoln Electric Holdings, Inc. (NASDAQ:LECO) On Your Watch List?
Explore Lincoln Electric Holdings's Fair Values from the Community and select yours Lincoln Electric Holdings, Inc. (NASDAQ:LECO) led the NASDAQGS gainers with a relatively large price hike in the past couple of weeks. The recent jump in the share price has meant that the company is trading at close to its 52-week high. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. However, could the stock still be trading at a relatively cheap price? Let's take a look at Lincoln Electric Holdings's outlook and value based on the most recent financial data to see if the opportunity still exists. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. What Is Lincoln Electric Holdings Worth? The stock seems fairly valued at the moment according to our valuation model. It's trading around 7.57% above our intrinsic value, which means if you buy Lincoln Electric Holdings today, you'd be paying a relatively fair price for it. And if you believe the company's true value is $220.58, there's only an insignificant downside when the price falls to its real value. Although, there may be an opportunity to buy in the future. This is because Lincoln Electric Holdings's beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity. View our latest analysis for Lincoln Electric Holdings Can we expect growth from Lincoln Electric Holdings? Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. With profit expected to grow by 32% over the next couple of years, the future seems bright for Lincoln Electric Holdings. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. What This Means For You Are you a shareholder? It seems like the market has already priced in LECO's positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value? Are you a potential investor? If you've been keeping an eye on LECO, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it's worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. If you'd like to know more about Lincoln Electric Holdings as a business, it's important to be aware of any risks it's facing. While conducting our analysis, we found that Lincoln Electric Holdings has 2 warning signs and it would be unwise to ignore them. If you are no longer interested in Lincoln Electric Holdings, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
GoHealth Second Quarter 2025 Earnings: Misses Expectations
Explore GoHealth's Fair Values from the Community and select yours GoHealth (NASDAQ:GOCO) Second Quarter 2025 Results Key Financial Results Revenue: US$94.0m (down 11% from 2Q 2024). Net loss: US$55.2m (loss widened by 105% from 2Q 2024). US$5.10 loss per share (further deteriorated from US$2.70 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period GoHealth Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 100%. Looking ahead, revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Insurance industry in the US. Performance of the American Insurance industry. The company's share price is broadly unchanged from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 3 warning signs for GoHealth you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
